In the context of exploring ICI coupled with chemotherapy, KELLY trial demonstrated encouraging anti-tumor activity of pembrolizumab plus eribulin in patients with heavily pretreated HR+/HER2- MBC [32]. Here, ERBB2 is linked to neoplasm.